Sonoma Pharmaceuticals Inc SNOA shares are trading lower by 11.9% to $0.19 Wednesday morning after the company announced a 1-for-20 reverse stock split.
The stock will trade on a split-adjusted basis starting August 30, 2024. This move aims to meet Nasdaq’s $1.00 minimum bid price requirement. As a result, every 20 shares of Sonoma’s common stock will be consolidated into one share, reducing the total outstanding shares from 20 million to 1 million.
No fractional shares will be issued; instead, shareholders will receive cash for any fractions. The authorized shares will also increase from 24 million to 50 million.
Should I Sell My SNOA Stock?
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Sonoma Pharmaceuticals have lost 75.9% year to date. This compares to the average annual return of -66.61%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
SNOA has a 52-week high of $1.02 and a 52-week low of $0.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
